Overview

IBI188 Combination Therapy in Solid Tumors

Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
A Phase Ib study aim to explore the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Treatments:
Bevacizumab
Carboplatin
Pemetrexed